Q-omics provides the consensus-scored KDM4B profile across patient tissues and cancer cell-line models. KDM4B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, KDM4B is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, KDM4B RNA expression shows 20,001 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BRCA, KIRC, and ACC as cancer lineages where KDM4B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KDM4B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KDM4B survival associations across molecular data types. KDM4B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KDM4B RNA expression–survival associations across cancer types. High KDM4B expression shows unfavorable associations in ACC and MESO, but favorable associations in BRCA, UCEC, UVM and HNSC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for KDM4B RNA expression.
This table summarizes KDM4B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for KDM4B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KDM4B shows lower tumor expression in THCA and higher tumor expression in KIRC, BRCA, CHOL, LUSC and BLCA. The KIRC box plot shows higher KDM4B RNA expression in tumor versus normal tissue (log2 FC = +1.042, t-test p < 0.001).
This table shows molecular features associated with KDM4B in patient tissues and cancer cell lines. In patient samples, KDM4B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, KDM4B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
